secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempus AI, Inc. (TEM)
CIK:        0001717115
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-206317
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempus AI Q1 revenue $348M (+36% YoY); raises FY2026 guidance to $1.59-1.60B
----------------------------------------------------------------------------

- Revenue $348.1M, +36% YoY; Diagnostics $261.1M (+34.7%), Data & Apps $87.0M (+40.5%).
- Net loss $(125.9)M vs $(68.0)M YoY, includes $56.3M stock comp and $32.3M unrealized securities losses.
- Adjusted EBITDA $(2.8)M, improved from $(16.2)M in Q1 2025.
- Raised FY2026 revenue guidance to $1.59-1.60B (~25% annual growth); maintains ~$65M Adj. EBITDA outlook.
- MRD test volume ~6,500, up ~500% YoY; expanded collaborations with Merck, Gilead, Northwestern Medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1717115/000119312526206317/0001193125-26-206317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1717115/000119312526206317/tem-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-206317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer